For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Myeloma Center

Bibliography

Found 55 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is C  [Clear All Filters]
2018
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al..  2018.  Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. Leuk Lymphoma. 59(6):1364-1374.
Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van-Besien K.  2018.  Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.. Leuk Lymphoma. :1-7.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
2017
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al..  2017.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.
Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D et al..  2017.  Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.. Clin Lymphoma Myeloma Leuk. 17(12):825-833.
Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D et al..  2017.  Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.. Clin Lymphoma Myeloma Leuk. 17(12):825-833.
van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A et al..  2017.  Cord blood chimerism and relapse after haplo-cord transplantation.. Leuk Lymphoma. 58(2):288-297.
van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A et al..  2017.  Haplo-cord transplant: HLA-matching determines graft dominance.. Leuk Lymphoma. 58(6):1512-1514.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM et al..  2017.  IgM myeloma: A multicenter retrospective study of 134 patients.. Am J Hematol. 92(8):746-751.
Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM et al..  2017.  IgM myeloma: A multicenter retrospective study of 134 patients.. Am J Hematol. 92(8):746-751.
Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM et al..  2017.  IgM myeloma: A multicenter retrospective study of 134 patients.. Am J Hematol. 92(8):746-751.
Moreau P, Joshua D, Chng W-J, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R et al..  2017.  Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.. Leukemia. 31(1):115-122.
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T et al..  2017.  A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.. Biol Blood Marrow Transplant. 23(6):930-937.
2016
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
A Stewart K, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ et al..  2016.  Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.. J Clin Oncol. 34(32):3921-3930.
2015
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al..  2015.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.